金天格胶囊对原发性骨质疏松症患者疼痛的影响：一项系统评价与Meta分析

The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis.

作者信息

Li Wei, Ye Baisheng, Meng Shilong, Huang Zhen, Jiang Xin, Qie Fengqing, Liu Yaosheng, Shi Xiaolin, Li Miaoer

机构信息

Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang Province, China.

The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.

出版信息

BMC Musculoskelet Disord. 2025 May 13;26(1):465. doi: 10.1186/s12891-025-08694-w.

DOI:10.1186/s12891-025-08694-w

PMID:40361081

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12070584/

Abstract

BACKGROUND

To evaluate the effectiveness of Jintiange capsules (JTG) in relieving pain in patients with primary osteoporosis (POP).

METHODS

A systematic review of the literature was conducted through seven databases, including PubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure, Wanfang Database and SinoMed, from inception to October 2023. The control group was given conventional anti-osteoporosis drug therapy such as Alfacalcidol soft capsules, Alendronate sodium tablets, Caltrate D3, etc. The experimental group was treated with JTG alone or in combination with JTG on the basis of the drugs used in the control group. The primary outcome measure was the visual analog scale (VAS). Stata SE-64 software was used to conduct meta-analyses of the final included studies.

RESULTS

A total of 2916 participants were included in 21 articles. The results of meta-analysis showed that JTG relieved pain (WMD: -2.51; 95% CI: -3.30, -1.71; p < 0.05), improved the bone mineral density (BMD) of femoral neck (WMD: 0.83; 95% CI: 0.33, 1.33; p < 0.05) and lumbar (WMD: 1.14; 95% CI: 0.67, 1.62; p < 0.05), improved oswestry disability index (ODI) (WMD: -1.79; 95% CI: -3.05, -0.54; p < 0.05), enhanced timed up and go test (TUG) (WMD: -2.61; 95% CI: -4.60, -0.62; p < 0.05) and decreased fracture incidence (WMD: 0.37; 95% CI: 0.15, 0.93; p < 0.05).

CONCLUSION

In terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP).

摘要

背景

评估金天格胶囊（JTG）缓解原发性骨质疏松症（POP）患者疼痛的有效性。

方法

通过七个数据库进行文献系统综述，包括PubMed、Web of Science、Cochrane图书馆、Embase、中国知网、万方数据库和中国生物医学文献数据库，检索时间从建库至2023年10月。对照组给予常规抗骨质疏松药物治疗，如阿法骨化醇软胶囊、阿仑膦酸钠片、钙尔奇D3等。实验组单独使用JTG或在对照组用药基础上加用JTG。主要结局指标为视觉模拟评分（VAS）。使用Stata SE - 64软件对最终纳入的研究进行荟萃分析。

结果

21篇文章共纳入2916名参与者。荟萃分析结果显示，JTG可缓解疼痛（加权均数差：-2.51；95%可信区间：-3.30，-1.71；p < 0.05），提高股骨颈骨密度（BMD）（加权均数差：0.83；95%可信区间：0.33，1.33；p < 0.05）和腰椎骨密度（加权均数差：1.14；95%可信区间：0.67，1.62；p < 0.05），改善奥斯陆残疾指数（ODI）（加权均数差：-1.79；95%可信区间：-3.05，-0.54；p < 0.05），增强计时起立行走测试（TUG）（加权均数差：-2.61；95%可信区间：-4.60，-0.62；p < 0.05）并降低骨折发生率（加权均数差：0.37；95%可信区间：0.15，0.93；p < 0.05）。